1. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
- Author
-
Gerhard Rogler, Jan Borovicka, Benjamin Misselwitz, Stephan R. Vavricka, Pierre Michetti, Christine N. Manser, Pascal Frei, Luc Biedermann, Milos Spasojevic, Frank Seibold, Alain M. Schoepfer, Jonas Zeitz, Thomas Greuter, Swiss IBDnet, Michael Scharl, Alex Straumann, University of Zurich, and Biedermann, Luc
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Population ,610 Medicine & health ,Certolizumab ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Crohn Disease ,Maintenance therapy ,Interquartile range ,Surveys and Questionnaires ,Internal medicine ,Humans ,Medicine ,2715 Gastroenterology ,Registries ,030212 general & internal medicine ,Certolizumab pegol ,education ,Crohn's disease ,education.field_of_study ,Tumor Necrosis Factor-alpha ,business.industry ,Gastroenterology ,General Medicine ,Middle Aged ,medicine.disease ,10219 Clinic for Gastroenterology and Hepatology ,Treatment Outcome ,Private practice ,Cohort ,Certolizumab Pegol ,Disease Progression ,Female ,030211 gastroenterology & hepatology ,business ,Follow-Up Studies ,medicine.drug - Abstract
Background: Long-term data of certolizumab pegol (CZP) in Crohn's disease (CD) from pivotal registry trials are limited. We therefore aimed to evaluate the long-term efficacy of CZP in clinical practice in Switzerland. Methods: In the First Approved Certolizumab Therapeutic Experience in Switzerland-III phase IV multicenter cohort, patients receiving CZP were prospectively included all over Switzerland in (non-) academic hospitals and private practice. Results: We included 104 CD patients (52 male; only 22.1% anti-tumor necrosis factor (TNF) naïve, CZP as third anti-TNF agent in 46.2%) with follow-up time between 6 weeks up to 5 years. During treatment with CZP, we observed a significant decrease of the Harvey Bradshaw Index from a median of 7 at baseline (interquartile range 4-11) to 4, 5, 4, 3, 3, and 2 at weeks 6, 26, 52, 78, 104, and 156, respectively. While anti-TNF naïve patients showed a significantly better response at the end of induction, during CZP maintenance therapy response was similar as compared to anti-TNF experienced patients as well as between patients with a short (0-5 years) vs. long duration of disease (>5 years). Conclusions: CZP is an effective long-term treatment option, including CD patients with long disease duration and prior treatment with 1 or 2 anti-TNF agents.
- Published
- 2017
- Full Text
- View/download PDF